The NIH HEAL Initiative offers this grant for multisite clinical trials on acute and chronic sickle cell disease (SCD) pain management. It supports efficacy/effectiveness trials of pharmacologic, nonpharmacologic, or multicomponent interventions. Opioid use can continue, but not solely. Trials should assess impact on psychological/functional outcomes, improving patient well-being and quality of life. Research on stigma, healthcare system barriers, and social factors affecting pain care is encouraged. Investigators must collect biological/psychological markers and thoroughly characterize participants. The grant advances diverse, evidence-based strategies for enhanced SCD pain care.
Opportunity ID: 342286
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AT-23-002 |
| Funding Opportunity Title: | HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.213 — Research and Training in Complementary and Integrative Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 13, 2022 |
| Last Updated Date: | Jul 13, 2022 |
| Original Closing Date for Applications: | Nov 21, 2022 |
| Current Closing Date for Applications: | Nov 21, 2022 |
| Archive Date: | Dec 27, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) Independent school districts County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Special district governments Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Native American tribal organizations (other than Federally recognized tribal governments) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to support multisite efficacy or effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed. However, opioid medication use alone should not be the only intervention studied. Trials supported under this initiative may also address the impact of these approaches on related psychological and functional outcomes to support improved overall well-being and quality of life. In addition, studies that address stigma, structural health care system, and social factors that may hinder quality comprehensive pain care for patients with SCD are also of interest. Investigators are encouraged to include the collection of well-justified biological markers or psychological processes that have demonstrated that they may mediate pain outcomes. Trials should collect sufficient measures to phenotypeclinically characterize participants such as type of pain, variability of pain, co-occurring conditions, and social determinants of health. The studies must address questions within the mission and research interests of the NIH HEAL Initiative and evaluate preventive or treatment strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, behavioral interventions, rehabilitation strategies, complementary interventions, integrated approaches, and delivery system strategies in well controlled trials in patients with SCD to manage acute and/or chronic pain. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AT-23-002.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 342286 Full Announcement-RFA-AT-23-002 -> RFA-AT-23-002-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00275914 | Oct 21, 2022 | Nov 21, 2022 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278457 | Nov 15, 2022 | Nov 21, 2022 | View |
Package 1
Mandatory forms
342286 RR_SF424_5_0-5.0.pdf
342286 PHS398_CoverPageSupplement_5_0-5.0.pdf
342286 RR_OtherProjectInfo_1_4-1.4.pdf
342286 PerformanceSite_4_0-4.0.pdf
342286 RR_KeyPersonExpanded_4_0-4.0.pdf
342286 RR_Budget_3_0-3.0.pdf
342286 PHS398_ResearchPlan_4_0-4.0.pdf
342286 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
342286 RR_SubawardBudget30_3_0-3.0.pdf
342286 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
342286 RR_SF424_5_0-5.0.pdf
342286 PHS398_CoverPageSupplement_5_0-5.0.pdf
342286 RR_OtherProjectInfo_1_4-1.4.pdf
342286 PerformanceSite_4_0-4.0.pdf
342286 RR_KeyPersonExpanded_4_0-4.0.pdf
342286 RR_Budget_3_0-3.0.pdf
342286 PHS398_ResearchPlan_5_0-5.0.pdf
342286 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
342286 RR_SubawardBudget30_3_0-3.0.pdf
342286 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
